TABLE 3

Association of 18F-FDG PET Functional Parameters and EBV DNA Copy Number with Clinicopathologic Characteristics of NPC Patients

TumorNodalTotalTumorNodalEBV DNA
CharacteristicnTLG (g/mL × mL)PTLG (g/mL × mL)PTLG (g/mL × mL)PSUVmax (g/mL)PSUVmax (g/mL)PCopy/mLP
Sex
 Female2483 ± 930.22670 ± 950.714153 ± 1220.10011.1 ± 4.60.8658.0 ± 5.40.6812,786 ± 7,9520.106
 Male84161 ± 227147 ± 322308 ± 39011.7 ± 6.39.2 ± 7.73,707 ± 1,1747
Age (y)*
 <47.55497 ± 1070.227143 ± 3440.968240 ± 3650.22011.3 ± 5.50.8188.8 ± 7.20.8272,264 ± 7,1000.002
 >47.554190 ± 265116 ± 222307 ± 34311.8 ± 6.39.0 ± 7.54,741 ± 13,431
T stage†
 T1–T25344 ± 46<0.001110 ± 2070.848155 ± 205<0.00110.0 ± 5.90.0018.3 ± 7.20.5312,270 ± 6,4550.014
 T3–T454237 ± 254147 ± 353384 ± 42813.0 ± 5.69.4 ± 7.54,761 ± 13,766
N stage†
 N0–N155137 ± 2150.72538 ± 70<0.001176 ± 2150.00111.7 ± 6.40.8836.3 ± 6.1<0.0013,289 ± 12,8970.026
 N2–N352146 ± 199224 ± 389370 ± 43811.3 ± 5.411.6 ± 7.53,779 ± 8,199
Overall stage†
 I–II2948 ± 53<0.00142 ± 750.00291 ± 81<0.00111.0 ± 7.30.3375.4 ± 5.50.001395 ± 8190.001
 III–IV78176 ± 231160 ± 331337 ± 39211.7 ± 5.410.2 ± 7.54,692 ± 12,474
World Health Organization‡
 I4114 ± 170115 ± 125230 ± 14010.6 ± 3.911.0 ± 4.41,069 ± 950
 II39177 ± 2090.247161 ± 3860.750338 ± 4320.08013.1 ± 6.40.0679.5 ± 8.30.7764,563 ± 14,5900.246
 III63127 ± 212115 ± 226243 ± 31310.1 ± 4.38.5 ± 6.93,079 ± 8,299
 Other2115 ± 3926 ± 36141 ± 2.426.5 ± 19.64.9 ± 7.02,513 ± 3,532

  • ↵* Median value.

  • ↵† Data on TNM stage were lacking for 1 patient.

  • ↵‡ World Health Organization II vs. III.